Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP)

12.90
Delayed Data
As of Jul 30
 0.00 / 0.00%
Today’s Change
2.31
Today|||52-Week Range
14.40
+154.44%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.7B

Company Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. The company also has a portfolio of small molecule drug candidates, which are no longer a strategic focus of its development activities for which the company is seeking partners to pursue further development and commercialization. It is currently focused on two clinical stage product candidates: Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex. Ziopharm Oncology was founded on September 9, 2003 and is headquartered in Boston, MA.

Contact Information

ZIOPHARM Oncology, Inc.
Parris Building
Boston Massachusetts 02129
P:(617) 259-1970
Investor Relations:

Employees

Shareholders

Individual stakeholders27.41%
Other institutional26.71%
Mutual fund holders15.48%

Top Executives

Laurence James Neil CooperChief Executive Officer & Managing Director
Caesar J. BelbelCOO, Secretary, Chief Legal Officer & Executive VP
Kevin G. LafondChief Financial Officer, Treasurer, CAO & VP
Francois LebelChief Medical Officer, EVP-Research & Development
Lynn M. FerrucciSVP-Human Resources, Facilities & Administration